Pharmaconex is part of the Informa Markets Division of Informa PLC


Industry News

Stay ahead of the pack with our round-the-clock news service and thought leadership from industry experts. keeping you up-to-date with the latest developments and technological advancements in the Pharma industry.

Pharmaconex West Africa to Launch in Nigeria April 2024

Pharmaconex West Africa, the latest expansion of the successful Pharmaconex event series, will take place from 22-24 April 2024 at the Landmark Centre in Lagos, Nigeria.

The event will focus on Active Pharmaceutical Ingredients (APIs) & Generic APIs, Machinery & Process, Packaging Materials, and Finished Dosage Forms (FDF) and is open to all businesses involved in the pharmaceutical and medical laboratory sectors, including manufacturers, distributors, suppliers, consultants, researchers, and regulators.

Pilot operation of Egypt's 1st cancer drug factory begins

Chairwoman of ACDIMA International Olfat Ghorab issued a press statement Tuesday announcing the beginning of the pilot operation of the $1-billion worth factory specialized in cancer drugs in collaboration with an Italian firm.

Source: egypttoday

Egypt, Saudi Arabia sign 14 investment agreements worth $7.7B

The General Authority for Free Zones and Investment (GAFI) hosted Tuesday the signing of 14 agreements worth $7.7 billion between the Egyptian and Saudi sides in the sectors of infrastructure, logistics, port management, food industries, pharmaceuticals, traditional energy, renewable energy, e-payment, digital financial and information solutions.

Source: egypttoday

Pharma Innovation Council launches to drive global industry collaboration

Led by Alliance president Dr. Becky Upton, the 13 next-generation leaders from large global pharmaceutical companies reflect the diversity of membership viewpoints. The Council will explore common challenges at a grassroots level and seed ideas for new pre-competitive projects aligned with the Alliance’s strategic themes: Emerging sciences and Technology, Improving the Efficiency and Effectiveness of R&D, and Empowering the Patient.

Source: european pharmaceutical manufacturer 

Sustainability in the pharmaceutical industry

Sustainability is at the heart of the pharmaceutical industry’s day-to-day operations, with many skilled individuals working in sustainability roles.  We are starting to see initiatives from companies all across the world, from investment in renewables, to low-carbon inhalers, to net zero buildings, and some examples are featured here, demonstrating their commitment to tackling the challenges in building a greener pharmaceutical industry in the UK.

Source: abpi

The Rapid Rise of Egypt’s Medicine Regulator

First founded in 2019 as a new regulatory body independent from Egypt’s Ministry of Health, the Egyptian Drug Authority (EDA) has made significant progress over the last three years. Now recognised as one of the MEA region’s leading regulators, the EDA can point to several notable successes in Egypt’s battle against the COVID-19 pandemic.


Source: Pharmaboardroom

With buyout on Horizon, Amgen and Sanofi eye cash plays for rare disease drug maker

Complying with Irish takeover rules, Amgen alerted the London Stock Exchange Friday that “any offer by Amgen for Horizon is, or is likely to be, solely in cash.” Naturally, the company caveated that there can “be no certainty” an offer will materialize.


Source: FIERCE Pharma

U.S. FDA declines to approve Y-mAbs's pediatric cancer drug

Dec 1 (Reuters) - The U.S. health regulator on Thursday declined to approve a treatment from Y-mAbs Therapeutics (YMAB.O) for a rare form of nerve cancer in pediatric patients, dragging the company's shares down 16% inextended trading. 


Source: Reuters

Egypt is pioneer in pharma industry localisation in MENA: General Manager of GSK

“Local pharma manufacturing in the MENA region represents between 32-57 percent of the consumed pharma packages. Egypt is one of the pioneering countries in terms of pharma industry localisation compared to other countries in the region, as local pharma production to consumption ratio in the Egyptian market is over 65 percent,”


Source: Ahram Online

Six Egypt Pharma Market Trends to Watch

Under the umbrella of its Vision 2030 economic transformation plan, Egypt is making strides towards covering its over 100 million citizens through a universal healthcare insurance scheme that has already been rolled out on a pilot basis in certain areas of the country.


Source: Pharmaboardroom

Pharma expo in Cairo attracts industry professionals, firms

"The exhibition provides great opportunities to build relationships with prospects and existing clients as well as form new business networks," said Ahmed Hany, an engineer with Cairo-based Nama Group, which is an agent, distributor, and producer of quality products including medicines.


Source: Xinhua

U.S. adds 2.5 million Bavarian Nordic monkeypox vaccine doses, expects more in July

July 15 (Reuters) - The U.S. government has ordered an additional 2.5 million doses of Bavarian Nordic's (BAVA.CO) vaccine for use against monkeypox and expects more later this month to fight an outbreak of the viral disease. 


Source: Reuters

The Medicine Maker and NIBRT present the Biopharma Trends Leaders’ Report 2022

The COVID-19 pandemic has changed the world – and the biopharma industry. The industry has adopted new technologies and approaches to drug development – and has learned that it is possible to bring new therapies to patients in significantly reduced timelines. 


Source: The Medicine Maker

Egypt Outpacing Middle East and Africa’s Top Markets

Four years after Egypt enacted a new universal health law, the country’s pharmaceutical market has consolidated itself as the fastest growing in the Middle East and Africa, far outpacing Saudi Arabia, South Africa, the UAE and Algeria. With USD 6.3 billion in value, Egyptian pharma is about to double its size from 2017. 


Source: Pharma Boardroom

Bavarian Nordic monkeypox vaccine wins EU approval

OSLO, July 25 (Reuters) - Danish biotechnology company Bavarian Nordic (BAVA.CO) said on Monday the European Commission had given permission for its Imvanex vaccine to be marketed as protection against monkeypox, as recommended last week by the European Medicines Agency (EMA).


Source: Reuters

Five Key Trends in MEA Medtech

The Middle East and Africa (MEA) medtech market is expected to grow from a value of USD 16.6 billion in 2019 to USD 21.8 billion at a CAGR of 3.6 percent by 2027, according to Business Market Insights. Read on for five crucial trends impacting MEA medtech and how the industry stands to evolve in the coming years.


Source: Pharma Boardroom